Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1
Aged
Animals
Biomarkers, Tumor
/ metabolism
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Pancreatic Ductal
/ immunology
Cells, Cultured
Coculture Techniques
Female
Glucose Transporter Type 1
/ metabolism
Humans
Leukocytes, Mononuclear
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Metabolome
Mice
Mice, Transgenic
Pancreatic Juice
/ metabolism
Pancreatic Neoplasms
/ immunology
Programmed Cell Death 1 Receptor
/ immunology
Survival Rate
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
29
05
2019
revised:
30
10
2019
accepted:
28
01
2020
pubmed:
6
2
2020
medline:
11
11
2020
entrez:
6
2
2020
Statut:
ppublish
Résumé
Better understanding of pancreatic diseases, including pancreatic ductal adenocarcinoma (PDAC), is an urgent medical need, with little advances in preoperative differential diagnosis, preventing rational selection of therapeutic strategies. The clinical management of pancreatic cancer patients would benefit from the identification of variables distinctively associated with the multiplicity of pancreatic disorders. We investigated, by
Identifiants
pubmed: 32019781
pii: 2326-6066.CIR-19-0403
doi: 10.1158/2326-6066.CIR-19-0403
doi:
Substances chimiques
Biomarkers, Tumor
0
Glucose Transporter Type 1
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-505Informations de copyright
©2020 American Association for Cancer Research.